Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
APTOF 
DMD Digital Health Connections Group Inc (APTOF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: APTOF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.09M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 1 | Beta 1.01 | 52 Weeks Range 0.64 - 24.30 | Updated Date 06/30/2025 |
52 Weeks Range 0.64 - 24.30 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -16.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -135.46% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6321979 | Price to Sales(TTM) - |
Enterprise Value 6321979 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 2552430 | Shares Floating 2035664 |
Shares Outstanding 2552430 | Shares Floating 2035664 | ||
Percent Insiders 20.25 | Percent Institutions 7.4 |
Analyst Ratings
Rating 1 | Target Price 12.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
DMD Digital Health Connections Group Inc
Company Overview
History and Background
DMD Digital Health Connections Group Inc does not exist as a publicly traded US stock. The provided analysis is a template, and information about 'DMD Digital Health Connections Group Inc' cannot be accurately filled without a real company.
Core Business Areas
Leadership and Structure
No existing company to analyze. The response below is a template only.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
No existing company to analyze. The response below is a template only.
Positioning
No existing company to analyze. The response below is a template only.
Total Addressable Market (TAM)
No existing company to analyze. The response below is a template only.
Upturn SWOT Analysis
Strengths
- N
- o
- e
- x
- i
- s
- t
- i
- n
- g
- c
- o
- m
- p
- a
- n
- y
- t
- o
- a
- n
- a
- l
- y
- z
- e
- .
- T
- h
- e
- r
- e
- s
- p
- o
- n
- s
- e
- b
- e
- l
- o
- w
- i
- s
- a
- t
- e
- m
- p
- l
- a
- t
- e
- o
- n
- l
- y
- .
Weaknesses
- N
- o
- e
- x
- i
- s
- t
- i
- n
- g
- c
- o
- m
- p
- a
- n
- y
- t
- o
- a
- n
- a
- l
- y
- z
- e
- .
- T
- h
- e
- r
- e
- s
- p
- o
- n
- s
- e
- b
- e
- l
- o
- w
- i
- s
- a
- t
- e
- m
- p
- l
- a
- t
- e
- o
- n
- l
- y
- .
Opportunities
- N
- o
- e
- x
- i
- s
- t
- i
- n
- g
- c
- o
- m
- p
- a
- n
- y
- t
- o
- a
- n
- a
- l
- y
- z
- e
- .
- T
- h
- e
- r
- e
- s
- p
- o
- n
- s
- e
- b
- e
- l
- o
- w
- i
- s
- a
- t
- e
- m
- p
- l
- a
- t
- e
- o
- n
- l
- y
- .
Threats
- N
- o
- e
- x
- i
- s
- t
- i
- n
- g
- c
- o
- m
- p
- a
- n
- y
- t
- o
- a
- n
- a
- l
- y
- z
- e
- .
- T
- h
- e
- r
- e
- s
- p
- o
- n
- s
- e
- b
- e
- l
- o
- w
- i
- s
- a
- t
- e
- m
- p
- l
- a
- t
- e
- o
- n
- l
- y
- .
Competitors and Market Share
Key Competitors
Competitive Landscape
No existing company to analyze. The response below is a template only.
Growth Trajectory and Initiatives
Historical Growth: No existing company to analyze. The response below is a template only.
Future Projections: No existing company to analyze. The response below is a template only.
Recent Initiatives: No existing company to analyze. The response below is a template only.
Summary
DMD Digital Health Connections Group Inc does not exist as a publicly traded entity. Thus, a proper analysis cannot be made. The template is provided. This company would need to be validated to fill the document.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (hypothetical)
- Yahoo Finance (hypothetical)
- Company website (hypothetical)
Disclaimers:
The analysis is based on the template requested, as the mentioned company does not exist. Any resemblance to actual companies is purely coincidental.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DMD Digital Health Connections Group Inc
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2014-10-23 | Chairman, President & CEO Dr. William G. Rice Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.aptose.com |
Full time employees 13 | Website https://www.aptose.com | ||
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.